VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through Third-Party Allotment.
VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD).
- VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD).
- With the completion of this fundraising round, the total amount of funds raised by VCCT now amounts to 1.7 billion yen ($11.3 million USD).
- VCCT is dedicated to the development and application of cutting-edge cell therapy treatments focusing on retinal diseases.
- As a front runner in regenerative medicine research, VCCT has accumulated a wealth of clinical expertise in this field.